Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025

MOUNTAIN VIEW, Calif. & SAN DIEGO–(BUSINESS WIRE)–Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, today announced that its majority-owned subsidiary, Pearsanta, Inc. (“Pearsanta”), has entered into a Market Development Collaboration Agreement (the “Agreement”) with women’s health pioneer Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM) focused on Pearsanta’s blood-based diagnostic test for endometriosis.